Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia von Dorrance, A M, Neviani, P, Ferenchak, G J, Huang, X, Nicolet, D, Maharry, K S, Ozer, H G, Hoellarbauer, P, Khalife, J, Hill, E B, Yadav, M, Bolon, B N, Lee, R J, Lee, L J, Croce, C M, Garzon, R, Caligiuri, M A, Bloomfield, C D, Marcucci, G

Volltext

Effects of a beverage containing an enzymatically induced-viscosity dietary fiber, with or without fructose, on the postprandial glycemic response to a high glycemic index food in... von WOLF, B. W, WOLEVER, T. M. S, LAI, C. S, BOLOGNESI, C, RADMARD, R, MAHARRY, K. S, GARLEB, K. A, HERTZLER, S. R, FIRKINS, J. L

Volltext

Inpatient Computer-Based Standing Orders vs Physician Reminders to Increase Influenza and Pneumococcal Vaccination Rates: A Randomized Trial von Dexter, Paul R, Perkins, Susan M, Maharry, Kati S, Jones, Kathy, McDonald, Clement J

Volltext

Supplemental Fructose Attenuates Postprandial Glycemia in Zucker Fatty fa/fa Rats von Wolf, Bryan W., Humphrey, Phillip M., Hadley, Craig W., Maharry, Kati S., Garleb, Keith A., Firkins, Jeffrey L.

Volltext

Inpatient Computer-based Standing Orders vs Physician Reminders to Increase Influenza and Pneumococcal Vaccination Rates: a Randomized Trial. JAMA 2004 Nov 17; 292(19): 2366-71 von Dexter Perkins SM, Maharry KS, Jones K, McDonald CJ

Volltext

Inpatient Computer-based Standing Orders vs Physician Reminders to Increase Influenza and Pneumococcal Vaccination Rates: a Randomized Trial. JAMA 2004 Nov 17; 292(19): 2366-71 von Dexter Perkins SM, Maharry KS, Jones K, McDonald CJ

Volltext

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer von Kopetz, Scott, Grothey, Axel, Yaeger, Rona, Van Cutsem, Eric, Desai, Jayesh, Yoshino, Takayuki, Wasan, Harpreet, Ciardiello, Fortunato, Loupakis, Fotios, Hong, Yong Sang, Steeghs, Neeltje, Guren, Tormod K, Arkenau, Hendrik-Tobias, Garcia-Alfonso, Pilar, Pfeiffer, Per, Orlov, Sergey, Lonardi, Sara, Elez, Elena, Kim, Tae-Won, Schellens, Jan H.M, Guo, Christina, Krishnan, Asha, Dekervel, Jeroen, Morris, Van, Calvo Ferrandiz, Aitana, Tarpgaard, L.S, Braun, Michael, Gollerkeri, Ashwin, Keir, Christopher, Maharry, Kati, Pickard, Michael, Christy-Bittel, Janna, Anderson, Lisa, Sandor, Victor, Tabernero, Josep

Volltext

Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study von Li, Zejuan, Herold, Tobias, He, Chunjiang, Valk, Peter J M, Chen, Ping, Jurinovic, Vindi, Mansmann, Ulrich, Radmacher, Michael D, Maharry, Kati S, Sun, Miao, Yang, Xinan, Huang, Hao, Jiang, Xi, Sauerland, Maria-Cristina, Büchner, Thomas, Hiddemann, Wolfgang, Elkahloun, Abdel, Neilly, Mary Beth, Zhang, Yanming, Larson, Richard A, Le Beau, Michelle M, Caligiuri, Michael A, Döhner, Konstanze, Bullinger, Lars, Liu, Paul P, Delwel, Ruud, Marcucci, Guido, Lowenberg, Bob, Bloomfield, Clara D, Rowley, Janet D, Bohlander, Stefan K, Chen, Jianjun

Volltext

Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia von Pastore, Friederike, Dufour, Annika, Benthaus, Tobias, Metzeler, Klaus H, Maharry, Kati S, Schneider, Stephanie, Ksienzyk, Bianka, Mellert, Gudrun, Zellmeier, Evelyn, Kakadia, Purvi M, Unterhalt, Michael, Feuring-Buske, Michaela, Buske, Christian, Braess, Jan, Sauerland, Maria Cristina, Heinecke, Achim, Krug, Utz, Berdel, Wolfgang E, Buechner, Thomas, Woermann, Bernhard, Hiddemann, Wolfgang, Bohlander, Stefan K, Marcucci, Guido, Spiekermann, Karsten, Bloomfield, Clara D, Hoster, Eva

Volltext

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia von Niederwieser, C, Kohlschmidt, J, Volinia, S, Whitman, S P, Metzeler, K H, Eisfeld, A-K, Maharry, K, Yan, P, Frankhouser, D, Becker, H, Schwind, S, Carroll, A J, Nicolet, D, Mendler, J H, Curfman, J P, Wu, Y-Z, Baer, M R, Powell, B L, Kolitz, J E, Moore, J O, Carter, T H, Bundschuh, R, Larson, R A, Stone, R M, Mrózek, K, Marcucci, G, Bloomfield, C D

Volltext

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy von Whitman, S P, Kohlschmidt, J, Maharry, K, Volinia, S, Mrózek, K, Nicolet, D, Schwind, S, Becker, H, Metzeler, K H, Mendler, J H, Eisfeld, A-K, Carroll, A J, Powell, B L, Carter, T H, Baer, M R, Kolitz, J E, Park, I-K, Stone, R M, Caligiuri, M A, Marcucci, G, Bloomfield, C D

Volltext

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia von Metzeler, Klaus H., Hummel, Manuela, Bloomfield, Clara D., Spiekermann, Karsten, Braess, Jan, Sauerland, Maria-Cristina, Heinecke, Achim, Radmacher, Michael, Marcucci, Guido, Whitman, Susan P., Maharry, Kati, Paschka, Peter, Larson, Richard A., Berdel, Wolfgang E., Büchner, Thomas, Wörmann, Bernhard, Mansmann, Ulrich, Hiddemann, Wolfgang, Bohlander, Stefan K., Buske, Christian

Volltext

The Role of NRG1 in the Predisposition to Papillary Thyroid Carcinoma von He, Huiling, Li, Wei, Liyanarachchi, Sandya, Wang, Yanqiang, Yu, Lianbo, Genutis, Luke K, Maharry, Sophia, Phay, John E, Shen, Rulong, Brock, Pamela, de la Chapelle, Albert

Volltext

Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study von MARCUCCI, Guido, MROZEK, Krzysztof, STERLING, Lisa J, VARDIMAN, James W, SCHIFFER, Charles A, CARROLL, Andrew J, LARSON, Richard A, BLOOMFIELD, Clara D, RUPPERT, Amy S, MAHARRY, Kati, KOLITZ, Jonathan E, MOORE, Joseph O, MAYER, Robert J, PETTENATI, Mark J, POWELL, Bayard L, EDWARDS, Colin G

Volltext

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8 von Becker, H, Maharry, K, Mrózek, K, Volinia, S, Eisfeld, A-K, Radmacher, M D, Kohlschmidt, J, Metzeler, K H, Schwind, S, Whitman, S P, Mendler, J H, Wu, Y-Z, Nicolet, D, Paschka, P, Powell, B L, Carter, T H, Wetzler, M, Kolitz, J E, Carroll, A J, Baer, M R, Caligiuri, M A, Stone, R M, Marcucci, G, Bloomfield, C D

Volltext

Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia von Walker, Christopher J, Kohlschmidt, Jessica, Eisfeld, Ann-Kathrin, Mrózek, Krzysztof, Liyanarachchi, Sandya, Song, Chi, Nicolet, Deedra, Blachly, James S, Bill, Marius, Papaioannou, Dimitrios, Oakes, Christopher C, Giacopelli, Brian, Genutis, Luke K, Maharry, Sophia E, Orwick, Shelley, Archer, Kellie J, Powell, Bayard L, Kolitz, Jonathan E, Uy, Geoffrey L, Wang, Eunice S, Carroll, Andrew J, Stone, Richard M, Byrd, John C, de la Chapelle, Albert, Bloomfield, Clara D

Volltext

SO-21 Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study) von Velez, L., Trevino, T., Kopetz, S., Grothey, A., Yaeger, R., Gollerkeri, A., Maharry, K., Tabernero, J.

Volltext

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid... von Metzeler, K H, Maharry, K, Kohlschmidt, J, Volinia, S, Mrózek, K, Becker, H, Nicolet, D, Whitman, S P, Mendler, J H, Schwind, S, Eisfeld, A-K, Wu, Y-Z, Powell, B L, Carter, T H, Wetzler, M, Kolitz, J E, Baer, M R, Carroll, A J, Stone, R M, Caligiuri, M A, Marcucci, G, Bloomfield, C D

Volltext

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–muta... von Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Gollerkeri, A., Maharry, K., Loupakis, F., Hong, Y., Steeghs, N., Guren, T., Arkenau, H., García Alfonso, P., Sandor, V., Christy-Bittel, J., Anderson, L., Tabernero, J.

Volltext

BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E m... von Van Cutsem, E., Cuyle, P., Huijberts, S., Schellens, J., Elez, E., Yaeger, R., Fakih, M., Montagut, C., Peeters, M., Desai, J., Yoshino, T., Ciardiello, F., Wasan, H., Maharry, K., Christy-Bittel, J., Gollerkeri, A., Kopetz, S., Grothey, A., Tabernero, J.

Volltext